A Phase I Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2′-Methoxyethyl Antisense Oligonucleotide to Clusterin, in Patients With Localized Prostate Cancer | Zendy

Kim N. | Zendy; Elizabeth A. Eisenhauer | Zendy; Ladan Fazli | Zendy; Edward C. Jones | Zendy; S. Larry Goldenberg | Zendy; Jean Powers | Zendy; Dongsheng Tu | Zendy; Martin Gleave | Zendy

Open Access

A Phase I Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2′-Methoxyethyl Antisense Oligonucleotide to Clusterin, in Patients With Localized Prostate Cancer

Author(s) -

Kim N.,

Elizabeth A. Eisenhauer,

Ladan Fazli,

Edward C. Jones,

S. Larry Goldenberg,

Jean Powers,

Dongsheng Tu,

Martin Gleave

Publication year - 2005

Publication title -

jnci journal of the national cancer institute

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.797

H-Index - 356

eISSN - 1460-2105

pISSN - 0027-8874

DOI - 10.1093/jnci/dji252

Subject(s) - clusterin , prostate cancer , prostate , lncap , pharmacokinetics , medicine , prostatectomy , urology , cancer , cmax , endocrinology , cancer research , andrology , chemistry , apoptosis , biochemistry

Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment resistance. OGX-011 is a 2'-methoxyethyl modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA and has been reported to inhibit clusterin expression and enhance drug efficacy in xenograft models. The primary objective of this clinical study was to determine a biologically effective dose of OGX-011 that would inhibit clusterin expression in human cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research